Nitto-denko Corporation

Banyu Pharmaceutical Co. Ltd

Msd K.k.

Daisuke Tsukahara

Yasunari Ooyabu

Nagaaki Sato

Takashi Kondo

Kazuhiro Fuke

Makoto Ishikawa

Hiroyuki Katayama

Eiji Toyoda

Makoto Jitsuoka

Yoshio Ogino

Shigeru Tokita

Kazuhiro Ikemura

Tsuyoshi Nagase

Teruyuki Nishimura

Katsumasa Nonoshita

Norikazu Ohtake

Munehisa Mitani

Fumiko Sakai

Keisuke Arakawa

Yoshikazu Nagae

Hiroshi Nakashima

Takuya Eto

Katsuyuki Nakabayashi

Jun-Ichi Eiki

An element-connecting board is a lead frame for allowing a light emitting diode element to be connected to one side thereof in a thickness direction. The element-connecting board includes the lead frame which is provided with a plurality of leads disposed with spaces from each other and a first insulating resin portion which is light reflective and fills the spaces.

Element connecting board, producing method thereof, and light emitting diode device

Element-connecting board, producing method thereof, and light-emitting diode device

A method for producing a light emitting diode device includes the steps of preparing a laminate including, in order, a supporting layer, a constraining layer and an encapsulating resin layer, each formed in a thickness direction; cutting the encapsulating resin layer and the constraining layer in the laminate into a pattern corresponding to the light emitting diode element; removing a portion which does not correspond to the light emitting diode element in the encapsulating resin layer and the constraining layer that are cut into the pattern; allowing the encapsulating resin layer corresponding to the light emitting diode element to be opposed to the light emitting diode element to be pressed in the direction where they come close to each other so as to encapsulate the light emitting diode element by the encapsulating resin layer; and removing the supporting layer and the constraining layer from the laminate.

Method for producing light emitting diode device

[Problem] To provide compounds useful as preventives or remedies for circular system disorders, nervous system disorders, metabolic disorders, reproduction system disorders, digestive system disorders, neoplasm, infectious diseases, etc., or as herbicides. [Means for Solution] A long-chain fatty acyl elongase inhibitor comprising, as the active ingredient thereof, a compound or a pharmaceutically-active salt thereof of a formula (I): [wherein W represents a hydrogen atom, a Calkyl, etc.; X represents an aryl, a heteroaryl, etc.; n indicates 0 or 1; Z represents a hydrogen atom, a Calkyl, etc.; A, A, Aand Aeach independently represent CH or N].

Long-chain fatty acyl elongase inhibitor comprising arylsulfonyl derivative as active ingredient

A compound of the following formula (I) or its pharmaceutically-acceptable salt is provided: [wherein X, Y, Z and W each independently represent a methine group or a nitrogen atom, provided that a case where all of X, Y, Z and W are methine group; A represents &#x2014;O&#x2014; or the like, B represents &#x2014;C(O)&#x2014; or the like, D represent &#x2014;(CH)m-, &#x2014;O&#x2014; or the like, and m2 represents 0 or 1; Q represents a methine group or a nitrogen atom; and R represents a group represented by the following formula (II-1) (wherein R, Rand Rindependently represent a lower alkyl group or the like]. 

Aza-substituted spiro derivatives

A compound represented by, e.g. the formula (I): [wherein X, Y, Z, and W each independently represent optionally substituted methine; A, B, and D each independently represent &#x2014;C(O)&#x2014;, etc.; Q represents a methine or a nitrogen; and R represents the formula (II-1), optionally substituted with lower alkyl, etc.; (wherein Rrepresents a lower alkyl, etc; and Rand Reach independently represents a lower alkyl, etc.)] or a pharmaceutically acceptable salt of the compound. The compounds and salt have antagonistic activity against a histamine H3 receptor or inverse agonistic activity against a histamine H3 receptor. They are useful in the prevention or treatment of metabolic diseases, circulatory diseases, or neurotic diseases.

Carbamoyl-substituted spiro derivative

A glucokinase activator is provided; and a remedy and/or a preventive for diabetes, or a remedy and/or a preventive for diabetes such as retinopathy, nephropathy, neurosis, ischemic cardiopathy, arteriosclerosis, and further a remedy and/or a preventive for obesity are provided. A glucokinase activator characterized by containing a 2-heteroaryl-substituted benzimidazole derivative of a general formula (I-0) or its pharmaceutically-acceptable salt: [in the formula, X represents a carbon atom or a nitrogen atom; (in the formula, X represents a carbon atom or a nitrogen atom); Rrepresents an aryl, etc.; Rrepresents a hydroxy, etc.; Rrepresents a &#x2014;Calkyl, etc.; Rrepresents a &#x2014;Calkyl, etc.; Xrepresents &#x2014;O&#x2014;, etc.; a indicates an integer of 1, 2 or 3; q indicates an integer of from 0 to 2; m indicates an integer of from 0 to 2].

2-heteroaryl-substituted benzimidazole derivative

An epoxy resin composition for semiconductor encapsulation which does not contain conductive foreign metallic particles having such a size that they cannot be detected and eliminated by the conventional method for eliminating conductive foreign metallic particles. The epoxy resin composition for semiconductor encapsulation comprises the following components (A) to (D). Conductive foreign metallic particles having a size of 20 &#x3bc;m or more are substantially not contained in the aforementioned epoxy resin composition.

Epoxy resin composition for semiconductor encapsulation and semiconductor device using the same

Growing community of inventors

Osaka, Japan

Daisuke Tsukahara